Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Adagene stock

Learn how to easily invest in Adagene stock.

Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.

How to buy Adagene stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ADAG. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading

tastytrade


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Adagene stock price (NASDAQ: ADAG)

Use our graph to track the performance of ADAG stocks over time.

Adagene shares at a glance

Information last updated 2023-03-15.
Latest market close$1.55
52-week range$0.90 - $4.84
50-day moving average $1.74
200-day moving average $1.58
Wall St. target price$12.53
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.58

Buy Adagene stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$0
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
tastytrade
Stocks, Options, ETFs, Cryptocurrency, Futures
$0
$0
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
$0
$0
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
E*TRADE
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
$0
$0
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.
loading

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Adagene stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adagene price performance over time

Historical closes compared with the close of $1.554 from 2023-03-20

1 week (2023-03-14) 8.67%
1 month (2023-02-22) -10.17%
3 months (2022-12-22) 26.34%
6 months (2022-09-22) 13.43%
1 year (2022-03-22) -65.23%
2 years (2021-03-22) -91.72%
3 years (2020-03-18) N/A
5 years (2018-03-18) N/A

Adagene financials

Revenue TTM $12.7 million
Gross profit TTM $10.2 million
Return on assets TTM -26.15%
Return on equity TTM -55.96%
Profit margin 0%
Book value $2.60
Market capitalisation $69.2 million

TTM: trailing 12 months

Adagene share dividends

We're not expecting Adagene to pay a dividend over the next 12 months.

You may also wish to consider:

Adagene share price volatility

Over the last 12 months, Adagene's shares have ranged in value from as little as $0.9 up to $4.842. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adagene's is 0.0692. This would suggest that Adagene's shares are less volatile than average (for this exchange).

To put Adagene's beta into context you can compare it against those of similar companies.

Adagene overview

Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. .

Frequently asked questions

What percentage of Adagene is owned by insiders or institutions?
Currently 10.676% of Adagene shares are held by insiders and 9.711% by institutions.
How many people work for Adagene?
Latest data suggests 259 work at Adagene.
When does the fiscal year end for Adagene?
Adagene's fiscal year ends in December.
Where is Adagene based?
Adagene's address is: Building C14, Suzhou, China, 215123
What is Adagene's ISIN number?
Adagene's international securities identification number is: US0053291078

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site